
Centogene appoints chief business officer
pharmafile | February 9, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Péter Adorján, centogene
Dr Péter Adorján has been appointed to the board of German rare disease firm Centogene and thereby extending its board to three members.
As chief business development officer Adorján will be in charge of expanding Centogene’s portfolio and bringing products to the market.
“Péter has nearly two decades of broad experience across the healthcare and IT industries which will bring valuable perspectives to our board and the company in general,” explains Professor Arndt Rolfs who is the chief executive and founder of Centogene.
After earning his PhD in informatics Adorján joined Epigenomics AG where he established and led the biostatistics department and later took over as vice president of manufacturing.
He then served as a senior consultant at McKinsey & Company in its business technology office. As global competence centre manager and director portfolio at T-Systems and Unisys, he was responsible for the IT services portfolio and go-to-market in Europe.






